Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc. ( we , Summit or the Company ) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company's pipeline of product candi…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$12.79B

EPS-$1.11

P/E-14.44

P/FCF-27.81

EV/EBITDA–

FCF Yield–

Div. Yield–

Net Debt/FCF1.5x

Summit Therapeutics Inc. intrinsic value

52-Week Range

$12.43$26.38

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$856M

▼ -387.8% YoY

Op. Margin

–

ROIC

–

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$460M

▼ -127.5% YoY

Op. Cash Flow (TTM)

-$458M

▼ -127.2% YoY

Net Debt

-$670M

Net Cash Position

Cash & Equiv.

$691M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with SMMT

CompareIntrinsic value

BMRNBiomarin Pharmaceutical Inc.

$58.51+1.77%51

BFRIBiofrontera Inc.

$0.87-6.34%30

BGMBGM Group Ltd.

$9.54-1.90%26

TGTXTG Therapeutics, Inc.

$61.18+5.34%57

RAREUltragenyx Pharmaceutical Inc.

$16.10-4.05%40

IDYAIdeaya Biosciences Inc.

$31.96-2.83%40

MIRMMirum Pharmaceuticals Inc.

$85.00-1.61%30

LEXXLexaria Bioscience Corp.

$3.49-7.43%10

Held by ETFs

SMMT is in 46 US ETFs. The largest of them, with SMMT's weight in each:

Summit Therapeutics (SMMT) in three numbers

Quality score: 10/100; Best check: net debt, -$670M. Weakest: return on capital, -74.4%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -14.44; Negative: a loss over the last twelve months. Price to free cash flow -27.81.; Financials

Questions about Summit Therapeutics

Is Summit Therapeutics a high-quality business?

Summit Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$670M, and its weakest is return on capital at -74.4%. The Quality tab shows every check against its target.

Does Summit Therapeutics (SMMT) pay a dividend?

No. Summit Therapeutics (SMMT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 17 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in SMMT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SMMT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.